Clinical Trial Update: The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) [Phase 2]

View source ↗

Summary

Phase 2 FLINT trial of obeticholic acid for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis reported results, showing histologic improvements …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Ocaliva (obeticholic acid)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2015-08-21